Archive


Category: acute lymphoblastic leukaemia

  • Blackstone revs up Autolus’ CAR with $250m fuel injection

    Private equity firm Blackstone has agreed to provide up to $250 million in financing to UK biotech Autolus Therapeutics, to help it take acute lymphoblastic leukaemia (ALL) CAR-T therapy obe-cel through late-stage development. The deal includes a $100 million equity stake, $50 million in financing as soon as it closes, and another $100 million on […]

  • Kite claims a first for CAR-T Tecartus in adult leukaemia

    The FDA has approved Kite Pharma’s Tecartus as a treatment for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL), making CAR-T therapy an option for an entirely new group of patients. The regulator cleared Tecartus (brexucabtagene autoleucel) for the new indication after a swift review that focused on the ZUMA-3 trial, which […]

  • ASCO21: Gilead sets up first FDA okay for adult ALL with Tecartus data

    Novartis’ Kymriah has had the CAR-T therapy market for acute lymphoblastic leukaemia (ALL) to itself so far, but Gilead Sciences’ Kite subsidiary is now looming in the rear view mirror – armed with new data for its already-filed rival Tecartus. Results of the phase 1/2 ZUMA-3 trial of Tecartus (brexucabtagene autoleucel) reported at the ongoing […]